Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich's conversation flits with ease from restaurants to solving the homeless crisis. His active mind has made him a serial inventor. But the founder and current CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, also has a razor-sharp focus when it comes to discussing his research. He wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. We've all seen it in elderly humans: Your grandparents are shrunken from their younger selves because their muscles no longer regenerate at the rate that they once did.

"When you go to the gym, you feel that burn which indicates that you have muscle damage. Your stem cells are responsible for repairing this damage and building your muscles," Watowich explains. Stem cells simply don't repair at the same rate in older individuals.

That's why, for example, elderly people who break a hip often fare poorly in the aftermath. It's not uncommon to face a difficult period of physical therapy following hip fracture surgery. Many patients do not return to independent living. And, the mortality rate one year after a hip fracture can be as high as 30 percent. If RLT-72484 proves to work as well in humans as it does in animal models, it could make it easier for patients to gain muscle after a fall.

But even for healthy older adults, muscle decline can cause problems. Travel is difficult if you don't have the muscle strength for long walks. Playing with grandchildren is a challenge if your mobility is compromised. Watowich's vision is to prevent muscle decline or at least slow it down.

The drug could also potentially help muscular dystrophy patients. The genetic diseases identified under that umbrella diagnosis all cause muscle loss before old age, sometimes even in infancy. If RLT-72484 fulfills its promise, it could allow MD patients to live more normal lives.

In the University of Texas Medical Branch study, the mice's muscle fiber doubled in size while muscle strength increased by 70 percent. The team published a study last month describing its results. The next year will be spent on studies necessary to win FDA approval to begin testing on humans.

Muscle loss isn't the only big problem Ridgeline Therapeutics is seeking to address. Obesity-linked diabetes is also in Watowich's sights. His team has come up with a small molecule that shrinks fat tissue in obese animals. In studies published last year, mice lost seven percent of their body weight in 10 days of treatment without changing their diets. The animals remained obese, but their fat deposits had decreased in size by 30 percent. The drug on its own cannot make obese people thin, but it may help diabetics to return to a non-diabetic state.

Ridgeline Therapeutics is based in the Texas Medical Center. Watowich explains that 98 percent of biotech companies fail, so it's his goal to "stay lean" and use the $4.2 million award the company received from the Department of Defense to get their technologies into human trials. The company will likely move to the Johnson & Johnson Innovation Labs collaboration space in the next few months.

But of course, what Ridgeline Technologies has to offer is most exciting of all. Remember, it's not going to allow you beat aging. But someday it may well help you to live without muscle loss or diabetes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Innovative coastline project on Bolivar Peninsula receives federal funding

flood mitigation

The Galveston’s Coastal Barrier Project recently received federal funding to the tune of $500,000 to support construction on its flood mitigation plans for the area previously devastated by Hurricane Ike in 2008.

Known as Ike Dike, the proposed project includes implementing the Galveston Bay Storm Surge Barrier System, including eight Gulf and Bay defense projects. The Bolivar Roads Gate System, a two-mile-long closure structure situated between Galveston Island and Bolivar Peninsula, is included in the plans and would protect against storm surge volumes entering the bay.

The funding support comes from U.S. Army Corps of Engineers (USACE) and will go toward the preconstruction engineering and design phase of Ecosystem Restoration feature G-28, the first segment of the Bolivar Peninsula and West Bay Gulf Intracoastal Waterway Shoreline and Island Protection.

Coastal Barrier Project - Galveston Projects

The project also includes protection of critical fish and wildlife habitat against coastal storms and erosion.

“The Coastal Texas Project is one of the largest projects in the history of the U.S. Army Corps of Engineers,” says Col. Rhett A. Blackmon, USACE Galveston District commander, in a statement. “This project is important to the nation for many reasons. Not only will it reduce risk to the vulnerable populations along the Texas coast, but it will also protect vital ecosystems and economically critical infrastructure vital to the U.S. supply chain and the many global industries located here.”

Hurricane Ike resulted in over $30 billion in storm-related damages to the Texas coast, reports the Coastal Barrier Project, and created a debris line 15 feet tall and 40 miles long in Chambers County. The estimated economic disruption due to Hurricane Ike exceeded $150 billion, FEMA reported.

The project is estimated to take two years to complete after construction starts and will cost between $4 billion and $6 billion, reports Texas A&M University at Galveston.

Houston organization selected for program to explore future foods in space health

research and development

What would we eat if we were forced to decamp to another planet? The most immediate challenges faced by the food industry and astronauts exploring outside Earth are being addressed by The Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine’s Center for Space Medicine’s newest project.

Earlier this month, TRISH announced the initial selection for its Space Health Ingress Program (SHIP) solicitation. Working with California Institute of Technology and Massachusetts Institute of Technology, the Baylor-based program chose “Future Foods for Space: Mobilizing the Future Foods Community to Accelerate Advances in Space Health,” led by Dr. Denneal Jamison-McClung at the University of California, Davis.

“TRISH is bringing in new ideas and investigators to propel space health research,” says Catherine Domingo, TRISH operations lead and research administration associate at Baylor College of Medicine, in the release. “We have long believed that new researchers with fresh perspectives drive innovation and advance human space exploration and SHIP builds on TRISH’s existing efforts to recruit and support new investigators in the space health research field, potentially yielding and high-impact ideas to protect space explorers.”

The goal of the project is to develop sustainable food products and ingredients that could fuel future space travelers on long-term voyages, or even habitation beyond our home planet.

Jamison-McClung and her team’s goal is to enact food-related space health research and inspire the community thereof by mobilizing academic and food-industry researchers who have not previously engaged with the realm of space exploration. Besides growing and developing food products, the project will also address production, storage, and delivery of the nutrition created by the team.

To that end, Jamison-McClung and her recruits will receive $1 million over the course of two years. The goal of the SHIP solicitation is to work with first-time NASA investigators, bringing new minds to the forefront of the space health research world.

“As we look to enable safer space exploration and habitation for humans, it is clear that food and nutrition are foundational,” says Dr. Asha S. Collins, chair of the SHIP advisory board, in a press release. “We’re excited to see how accelerating innovation in food science for space health could also result in food-related innovations for people on Earth in remote areas and food deserts.”

Clean energy nonprofit CEO to step down, search for replacement to begin

moving on

Greentown Labs, which is co-located in the Boston and Houston areas, has announced its current CEO is stepping down after less than a year in the position.

The nonprofit's CEO and President Kevin Knobloch announced that he will be stepping down at the end of July 2024. Knobloch assumed his role last September, previously serving as chief of staff of the United States Department of Energy in President Barack Obama’s second term.

“It has been an honor to lead this incredible team and organization, and a true privilege to get to know many of our brilliant startup founders," Knobloch says in the news release. “Greentown is a proven leader in supporting early-stage climatetech companies and I can’t wait to see all that it will accomplish in the coming years.”

The news of Knobloch's departure comes just over a month after the organization announced that it was eliminating 30 percent of its staff, which affected 12 roles in Boston and six in Houston.

According the Greentown, its board of directors is expected to launch a national search for its next CEO.

“On behalf of the entire Board of Directors, I want to thank Kevin for his efforts to strengthen the foundation of Greentown Labs and for charting the next chapter for the organization through a strategic refresh process,” says Dawn James, Greentown Labs Board Chair, in the release. “His thoughtful leadership will leave a lasting impact on the team and community for years to come.”

Knobloch reportedly shifted Greentown's sponsorship relationships with oil companies, sparking "friction within the organization," according to the Houston Chronicle, which also reported that Knobloch said he intends to return to his clean energy consulting firm.

------

This article originally ran on EnergyCapital.